TORONTO, June 12, 2014 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") announced that Mr. Tony Melles has resigned from the Board, effective June 13, 2014.
Mr. Melles stated that "the urgent requirements of his work preclude him from devoting the time & attention required to the duties of board director; he wishes Biosign well and looks forward to seeing the company grow under its hard-working management team."
With this change, the Board now consists of Dr. Michael Gross (Chairman), Mr. Dennis Rygwalski (Chair of the Audit Committee), Mr. John-Peter Bradford, Mr. Brian Neill and Mr. Robert Kaul (Biosign CEO). The Company expects to replace Mr. Melles on the Board in the near future.
Biosign Chairman Michael Gross stated: "We are sorry to lose the service, counsel and enthusiasm of Tony Melles on our Board. In the short time he has been a member, his work with us has had a material impact on our ability to execute our plans. Biosign thanks Mr. Melles for his service and wishes him well in all his future endeavours."
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions including the Pulsewave™ Health Monitor and the Healthanywhere™ Patient monitoring / self-care platform. The Company's various software solutions, including Clinicserver™ and PencilThat™ offer industry-leading allied health clinic and patient centred care management. The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information: Biosign Contact Information: Robert Kaul, Chief Executive Officer, Biosign Technologies, Phone: (416) 218-9800 ext. 201, Email: firstname.lastname@example.org